Compare GSK plc (GSK) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Altria Group Inc — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while Altria Group Inc trades at $72.13 (market cap $117.76B). The key difference: Altria Group Inc is the larger of the two by market cap, and Altria Group Inc pays the higher dividend (6.01%). Which is the better fit depends on your goals.
| GSK | MO | |
|---|---|---|
Market Cap | $101.34B | $117.76B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $74.55 |
52-Week Low | $36.20 | $54.72 |
Enterprise Value | $121.95B | $138.83B |
Dividend Yield | 3.49% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
MO trades at $72.14, up 2.79% today, near the consensus price target of $71.00. Technicals are bearish with support at $70 and resistance at $72. The company reported Q1 2026 EPS of $1.32, beating estimates, but Q4 2025 missed. Revenue for 2025 was $20.14B with a net income margin of 39.52%. Recent news highlights its status as a Dividend King, with a focus on high yields and defensive qualities amid market volatility.
Outlook: MO offers a high dividend yield and stable cash flow, but faces risks from declining smoking trends and regulatory pressures. Analysts are mostly bullish (61.53% buy ratings), yet technical weakness and debt levels warrant caution. The stock presents income appeal but requires monitoring of earnings consistency and sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
